



## At a Glance Urea Cycle Disorders (UCD)

**Deficient enzyme:** NAGS- N-acetylglutamate synthetase  
CPS1- Carbamoyl phosphate synthetase  
OTC- Ornithine transcarbamylase  
ASS- Argininosuccinic acid synthetase (citrullinemia)  
ASL- Argininosuccinic acid lyase (also referred to as ASA-argininosuccinic aciduria)  
ARG1 - Arginase (argininemia)

**Deficient transporter:** Citrin (*note: nutrition treatment is very different and not covered here*)  
ORT1 – Ornithine translocase (HHH Syndrome)

**Toxic Metabolites:** Ammonia  
Argininosuccinic acid- in ASL deficiency  
Arginine- in arginase deficiency

**Mode of Diagnosis:** clinical presentation, family history, newborn screening (for ASS, ASL, ARG1, HHH Syndrome)

**Clinical presentation in untreated patients:** hyperammonemia caused neurotoxicity, poor feeding, growth failure, vomiting, seizures, lethargy, liver dysfunction, coma, death; late identified adolescents/adults- chronic neurological symptoms and dietary history of self-restricting dietary protein

**Treatment:** prevent catabolism, limit intact protein and provide essential amino acid medical food, supplement citrulline or arginine (except in arginase deficiency), provide nitrogen scavenging medications; degree of treatment varies based on residual enzyme activity/clinical presentation

**Goal Treatment Range\*:** Ammonia- normal (<35  $\mu\text{mol/L}$ ; <60 mcg/dL)  
Plasma glutamine- <900  $\mu\text{mol/L}$   
Plasma essential amino acids- maintain all within normal range  
Plasma arginine (in ARG1)- <300  $\mu\text{mol/L}$   
Plasma arginine (all other UCD)- 70 – 120  $\mu\text{mol/L}^2$

### Nutrient Needs by Age<sup>1</sup>

Age	Intact Protein g/kg/d	Essential Amino Acid (medical food; g/kg/d)	Total Protein g/kg/d
0-1 yr	0.8-1.1	0.4-1.1	1.2-2.2
1-7 yr	0.7-0.8	0.3-0.7	1.0-1.2
7-19 yr	0.3-1.0	0.4-0.7	0.8-1.4
>19 yr	0.6-0.7	0.2-0.5	0.8-1.0

### Starting a Diet

1. Determine goals for total protein (g) and percentage to be provided by intact protein vs essential amino acids (medical food). Consider 30-50% from essential amino acids for initial diet.
2. Calculate amount of intact protein source (breast milk, infant formula, food) and amount of medical food required to meet total protein (g) goal.
3. Calculate energy (kcal) provided by intact protein and medical food sources to ensure DRI for energy needs are met. Consider addition of protein-free calorie modular as needed to meet energy needs.
4. Consider use of enteral nutrition support in this population as anorexia is a common complication.
5. Patients with severe forms of UCD may require placement of a gastrostomy tube.

# Urea Cycle Disorders (UCD)

## Medical Food Therapy

	<b>Abbott</b> <a href="http://abbottnutrition.com">abbottnutrition.com</a>	<b>Mead Johnson</b> <a href="http://hcp.meadjohnson.com">hcp.meadjohnson.com</a>	<b>Nutricia</b> <a href="http://NutriciaMetabolics.com">NutriciaMetabolics.com</a>	<b>Vitaflo</b> <a href="http://www.VitafloUSA.com">www.VitafloUSA.com</a>
<b>Infant (0-1 yr)</b>	Cyclinex®-1	WND 1		
<b>Toddler &amp; Young Children</b>	Cyclinex-1® Cyclinex-2	WND 1 WND 2	UCD Anamix® Junior Essential Amino Acid Mix	UCD trio™ EAA supplement™
<b>Older Children &amp; Adults</b>	Cyclinex-2	WND 2	UCD Anamix Junior Essential Amino Acid Mix	UCD trio EAA supplement
<b>Protein Free Modular</b>	Pro-Phree®	PFD Toddler PFD 2	Duocal® Polycal™	S.O.S™ 25

## Supplementation <sup>1</sup>

L-Citrulline (OTC and CPS-1 deficiency): 100-200 mg/kg/d

L-Arginine (ASS and ASL deficiency): 100-300 mg/kg/d (100 mg/kg/d may be sufficient in ASL deficiency)

## Medical Therapy <sup>1</sup>

*Nitrogen scavenging medications* – use alternative pathways to remove nitrogen to prevent hyperammonemia while allowing for greater protein tolerance. Monitor branched chain amino acids.

Sodium Benzoate- binds with glycine to form hippurate, removes one nitrogen atom, then is excreted in urine

Sodium Phenylbutyrate- binds with glutamine to form phenylacetylglutamine, removes two nitrogen atoms, then is excreted in urine, 450-600 mg/kg/day or 9.9-13.0 g/m<sup>2</sup>/d when >20kg, generic available

Buphenyl® (Amgen- [www.amgen.com](http://www.amgen.com))

Olpruva™ (Zevra Therapeutics- [zevra.com](http://zevra.com))

Pheburane® (Medunik USA- [www.medunikusa.com](http://www.medunikusa.com))

Glycerol Phenylbutyrate- same mechanism of action as sodium phenylbutyrate but on a glycerol backbone, 4.5-11.2 mL/m<sup>2</sup>/d

Ravicti® (Amgen- [www.amgen.com](http://www.amgen.com))

Sodium Phenylacetate + Sodium Benzoate (IV only)

Ammonul® (Ucyclyd Pharma, Inc- [www.ucyclyd.com](http://www.ucyclyd.com))

*Carglumic acid*- a synthetic form of N-acetylglutamate synthase approved for NAGS deficiency, generic available ([www.etonpharma.com](http://www.etonpharma.com))

## Laboratory Monitoring

Plasma Amino Acids <sup>A</sup> (especially glutamine)  
Ammonia <sup>A</sup>

Ferritin, iron, folate, zinc, vitamin B12 <sup>B</sup>  
25-OH Vitamin D <sup>B</sup>

CBC <sup>B</sup>  
CMP <sup>B</sup>

A Weekly in infancy, 1-3 months thereafter

B At least annually or as indicated

## References

- MacLeod, E. Nutrition Management of Urea Cycle Disorders. In LE Bernstein, F Rohr, S van Calcar (Eds.) *Nutrition Management of Inherited Metabolic Diseases* (2<sup>nd</sup> Edition). Springer: 2021
- Häberle J, et.al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. *J Inherit Metab Dis*. 2019 Nov;42(6):1192-1230. doi: 10.1002/jimd.12100. Epub 2019 May 15. PMID: 30982989.